SCHEMBL921704

SCHEMBL921704

Nc1nc(F)ccc1C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAPRT Q6XQN6 2/20 0.47
GABRP O00591 3/20 0.46
GABRD O14764 3/20 0.46
GABRA1 P14867 3/20 0.46
GABRB1 P18505 3/20 0.46
GABRG2 P18507 3/20 0.46
GABRB3 P28472 3/20 0.46
GABRA5 P31644 3/20 0.46
GABRA3 P34903 3/20 0.46
GABRA2 P47869 3/20 0.46
GABRB2 P47870 3/20 0.46
GABRA4 P48169 3/20 0.46
GABRE P78334 3/20 0.46
GABRA6 Q16445 3/20 0.46
GABRG1 Q8N1C3 3/20 0.46
GABRG3 Q99928 3/20 0.46
GABRQ Q9UN88 3/20 0.46
KEAP1 Q14145 2/20 0.42
CYP1A2 P05177 2/20 0.41
KDM4E B2RXH2 6/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6837648 0.83 IKBKB (0.46) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL31253326 0.80 CYP1A2 (0.46) NAPRTGABRPGABRDGABRA1GABRB1
SCHEMBL7537222 0.80 CYP1A2 (0.46) NAPRTGABRPGABRDGABRA1GABRB1
SCHEMBL445478 0.78 NAPRT (0.50) NAPRTGABRPGABRDGABRA1GABRB1
SCHEMBL29551348 0.78 NAPRT (0.50) NAPRTGABRPGABRDGABRA1GABRB1
SCHEMBL920297 0.78 GABRP (0.64) NAPRTGABRPGABRDGABRA1GABRB1
SCHEMBL11179056 0.77 KDM4E (0.46) KDM4EALDH1A1MAPTGAAHPGD
SCHEMBL4635194 0.77 NAPRT (0.48) NAPRTGABRPGABRDGABRA1GABRB1
Hydrochloric Acid SCHEMBL2211447 0.77 NAPRT (0.48) NAPRTGABRPGABRDGABRA1GABRB1
SCHEMBL8666506 0.77 KDM4E (0.47) NAPRTGABRPGABRDGABRA1GABRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4383851-A CONTROLLING WILD OATS IN WHEAT THE DOW CHEMICAL COMPANY (US) 1983-05-17 US claimed
US-20250019383-A1 PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV Healthcare UK (No.5) Limited (GB) 2025-01-16 US disclosed
CN-119039288-A Pyrido [2,3-d ] pyrimidine derivatives as inhibitors of HIV replication VIIV保健英国第五有限公司 2024-11-29 CN disclosed
US-12129255-B2 Pyrido [2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2024-10-29 US disclosed
CN-114245795-B Pyrido [2,3-d ] pyrimidine derivatives as inhibitors of HIV replication VIIV保健英国第五有限公司 2024-08-06 CN disclosed
EP-3986561-B1 PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV HEALTHCARE UK NO 5 LTD (GB) 2024-02-14 EP disclosed
US-20230355626-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2023-11-09 US disclosed
US-20230212129-A1 QUINAZOLINE DERIVATIVES USEFUL AS SELECTIVE HDAC6 INHIBITORS Annji Pharmaceutical Co., Ltd. (TW) 2023-07-06 US disclosed
US-20230212129-A1 QUINAZOLINE DERIVATIVES USEFUL AS SELECTIVE HDAC6 INHIBITORS Annji Pharmaceutical Co., Ltd. (TW) 2023-07-06 US disclosed
EP-4114834-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV Healthcare UK (No.5) Limited (GB) 2023-01-11 EP disclosed
WO-2021176366-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV Healthcare UK (No.5) Limited (GB) 2021-09-10 WO disclosed
WO-2020254985-A1 PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV Healthcare UK (No.5) Limited (GB) 2020-12-24 WO disclosed
WO-2020254985-A1 PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV Healthcare UK (No.5) Limited (GB) 2020-12-24 WO disclosed
US-20110009454-A1 COMPOSITION FOR AGRICULTURAL USE FOR CONTROLLING OR PREVENTING PLANT DISEASES CAUSED BY PLANT PATHOGENS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-01-13 US disclosed
EP-2248423-A1 COMPOSITION FOR AGRICULTURAL USE FOR CONTROLLING OR PREVENTING PLANT DISEASES CAUSED BY PLANT PATHOGENS Sumitomo Chemical Company, Limited (JP) 2010-11-10 EP disclosed
US-5441955-A Tuberculosis PATHOGENESIS CORPORATION (US) 1995-08-15 US disclosed
WO-1995013807-A1 INDOLO[2,1-b]QUINAZOLINE-6,12-DIONE ANTIBACTERIAL COMPOUNDS AND METHODS OF USE THEREOF PATHOGENESIS CORPORATION (US) 1995-05-26 WO disclosed
US-4383851-A CONTROLLING WILD OATS IN WHEAT THE DOW CHEMICAL COMPANY (US) 1983-05-17 US disclosed
US-4383851-A CONTROLLING WILD OATS IN WHEAT THE DOW CHEMICAL COMPANY (US) 1983-05-17 US disclosed
US-4383851-A CONTROLLING WILD OATS IN WHEAT THE DOW CHEMICAL COMPANY (US) 1983-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212129-A1 QUINAZOLINE DERIVATIVES USEFUL AS SELECTIVE HDAC6 INHIBITORS HDAC6, HDAC1, HDAC5 NAPRT 1605/4885GABRP 3777/4885GABRD 3702/4885
US-20110009454-A1 COMPOSITION FOR AGRICULTURAL USE FOR CONTROLLING OR PREVENTING PLANT DISEASES CAUSED BY PLANT PATHOGENS WIZ, TST, NAT1 NAPRT 527/4885GABRP 3713/4885GABRD 3683/4885
US-20250019383-A1 PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION TYMP, TYMS, DPYD NAPRT 105/4885GABRP 2395/4885GABRD 3558/4885
US-12129255-B2 Pyrido [2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication TYMP, TYMS, DPYD NAPRT 105/4885GABRP 2395/4885GABRD 3558/4885
US-20230355626-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION EIF2AK2, POLR2E, POLR2H NAPRT 1288/4885GABRP 3435/4885GABRD 4264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.